The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response
Open accessAbstract
Gene regulation by cytokine-activated transcription factors of the signal transducer and activator of transcription (STAT) family requires serine phosphorylation within the transactivation domain (TAD). STAT1 and STAT3 TAD phosphorylation occurs upon promoter binding by an unknown kinase. Here, we show that the cyclin-dependent kinase 8 (CDK8) module of the Mediator complex phosphorylated regulatory sites within the TADs of STAT1, STAT3, and STAT5, including S727 within the STAT1 TAD in the interferon (IFN) signaling pathway. We also observed a CDK8 requirement for IFN-γ-inducible antiviral responses. Microarray analyses revealed that CDK8-mediated STAT1 phosphorylation positively or negatively regulated over 40% of IFN-γ-responsive genes, and RNA polymerase II occupancy correlated with gene expression changes. This divergent regulation occurred despite similar CDK8 occupancy at both S727 phosphorylation-dependent and -independent genes. These data identify CDK8 as a key regulator of STAT1 and antiviral responses and suggest a general role for CDK8 in STAT-mediated transcription. As such, CDK8 represents a promising target for therapeutic manipulation of cytokine responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In macrophages, CDK8 appears to be the main kinase driving STAT1 serine phosphorylation in response to IFN gamma stimulation”
From CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci (2020) · cites this paper as Bancerek et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Previous studies have described CDKs as regulators of STAT1 Ser phosphorylation in different systems”
From CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci (2020) · cites this paper as Bancerek et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Todaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Mediator and cohesin connect gene expression and chromatin architecture
Kagey, M. H., Newman, J. J., Bilodeau, S., Zhan, Y., Orlando, D. A., van Berkum, N. L., Ebmeier, C. C., Goossens, J., Rahl, P. B., Levine, S. S., et al. (2010) · Nature · doi:10.1038/nature09380 · Cited by 1,939
Self-citationTargeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81289-1 · Cited by 1,539
Serine phosphorylation of STATs
Decker, T., & Kovarik, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203481 · Cited by 887
Self-citationNuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719
CDK8 is a colorectal cancer oncogene that regulates β-catenin activity
Firestein, R., Bass, A. J., Kim, S. Y., Dunn, I. F., Silver, S. J., Guney, I., Freed, E., Ligon, A. H., Vena, N., Ogino, S., et al. (2008) · Nature · doi:10.1038/nature07179 · Cited by 692
Immune Control of Tuberculosis by IFN-γ-Inducible LRG-47
MacMicking, J. D., Taylor, G. A., & McKinney, J. D. (2003) · Science · doi:10.1126/science.1088063 · Cited by 685 · cited 1×
“Primary Irf1, Wars (also known as Ifp-53), and Ifi47 are each regulated by binding of the STAT1 homodimer to the IFN-g-activated sequence (GAS) in the promoter (MacMicking et al., 2003; Pine et al., 1994; Strehlow et al., 1993).”
Mastermind Recruits CycC:CDK8 to Phosphorylate the Notch ICD and Coordinate Activation with Turnover
Fryer, C. J., White, B., & Jones, K. A. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.014 · Cited by 627
Flagged first, then by citations
2 of the 53 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,418
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
The Mediator complex: a central integrator of transcription
Allen, B. L., & Taatjes, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3951 · Cited by 922
Self-citationMechanisms of Jak/STAT Signaling in Immunity and Disease
Villarino, A. V., Kanno, Y., Ferdinand, J. R., & O’Shea, J. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401867 · Cited by 564
Mediator kinase inhibition further activates super-enhancer-associated genes in AML
Pelish, H. E., Liau, B. B., Nitulescu, I. I., Tangpeerachaikul, A., Poss, Z. C., Silva, D. H. D., Caruso, B., Arefolov, A., Fadeyi, O., Christie, A. L., et al. (2015) · Nature · doi:10.1038/nature14904 · Cited by 406
Self-citationGenome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
Schneider, W. M., Luna, J. M., Hoffmann, H.-H., Rivera, F. J. S., Leal, A. A., Ashbrook, A. W., Pen, J. L., Ricardo-Lax, I., Michailidis, E., Peace, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.006 · Cited by 397
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
The Mediator complex and transcription regulation
Poss, Z. C., Ebmeier, C. C., & Taatjes, D. J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.840259 · Cited by 364
Self-citationMajoros, A., Platanitis, E., Kernbauer, E., Rosebrock, F., Müller, M. M., & Decker, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00029 · Cited by 333
Self-citationCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 381
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
Mills, R. J., Humphrey, S. J., Fortuna, P. R. J., Lor, M., Foster, S. R., Quaife-Ryan, G. A., Johnston, R. L., Dumenil, T. D., Bishop, C., Rudraraju, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.026 · Cited by 229
Transcriptional Regulation of Antiviral Interferon-Stimulated Genes
Wang, W., Xu, L., Su, J., Peppelenbosch, M. P., & Pan, Q. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.01.001 · Cited by 221
Differential Regulation of Type I and Type III Interferon Signaling
Stanifer, M. L., Pervolaraki, K., & Boulant, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061445 · Cited by 214
The Mediator Complex: At the Nexus of RNA Polymerase II Transcription
Jerónimo, C., & Robert, F. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.07.001 · Cited by 189
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Targeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N. P., Teng, M., Gray, N. S., & Johnstone, R. W. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 170
Poss, Z. C., Ebmeier, C. C., Odell, A. T., Tangpeerachaikul, A., Lee, T., Pelish, H. E., Shair, M. D., Dowell, R. D., Old, W. M., & Taatjes, D. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.030 · Cited by 170
Self-citationNPR1 Promotes Its Own and Target Gene Expression in Plant Defense by Recruiting CDK8
Chen, J., Mohan, R., Zhang, Y., Li, M., Chen, H., Palmer, I. A., Chang, M., Qi, G., Spoel, S. H., Mengiste, T. D., et al. (2019) · PLANT PHYSIOLOGY · doi:10.1104/pp.19.00124 · Cited by 150
Akamatsu, M., Mikami, N., Ohkura, N., Kawakami, R., Kitagawa, Y., Sugimoto, A., Hirota, K., Nakamura, N., Ujihara, S., Kurosaki, T., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2707 · Cited by 148
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
Dale, T. C., Clarke, P. A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.-J., Mallinger, A., Samant, R. S., Czodrowski, P., Müsil, D., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1952 · Cited by 146
Nan, Y., Wu, C., & Zhang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01758 · Cited by 146
CDK8/19 Mediator kinases potentiate induction of transcription by NFκB
Chen, M., Liang, J., Ji, H., Yang, Z., Altilia, S., Hu, B., Schronce, A., McDermott, M. S. J., Schools, G. P., Lim, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710467114 · Cited by 143
Kang, K., Bachu, M., Park, S. H., Kang, K., Bae, S., Park‐Min, K., & Ivashkiv, L. B. (2019) · Nature Communications · doi:10.1038/s41467-019-11147-3 · Cited by 145
Set1/COMPASS and Mediator are repurposed to promote epigenetic transcriptional memory
D’Urso, A., Takahashi, Y.-H., Xiong, B., Marone, J., Coukos, R., Randise-Hinchliff, C., Wang, J.-P., Shilatifard, A., & Brickner, J. H. (2016) · eLife · doi:10.7554/elife.16691 · Cited by 142
CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.012 · Cited by 132
Self-citationRegulatory functions of the Mediator kinases CDK8 and CDK19
Fant, C. B., & Taatjes, D. J. (2018) · Transcription · doi:10.1080/21541264.2018.1556915 · Cited by 131
Self-citationCzodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Pöschke, O., Busch, M., Rohdich, F., Eccles, S. A., Ortiz-Ruiz, M.-J., Schneider, R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00597 · Cited by 123
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 121
Rzymski, T., Mikuła, M., Żyłkiewicz, E., Dreas, A., Wiklik, K., Gołas, A., Wójcik, K., Masiejczyk, M., Wróbel, A., Dolata, I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16810 · Cited by 117
The two faces of Cdk8, a positive/negative regulator of transcription
Nemet, J., Jelicic, B., Rubelj, I., & Sopta, M. (2014) · Biochimie · doi:10.1016/j.biochi.2013.10.004 · Cited by 115
Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
Philip, S., Kumarasiri, M., Teo, T., Yu, M., & Wang, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00901 · Cited by 111
The Mediator kinase module: an interface between cell signaling and transcription
Luyties, O., & Taatjes, D. J. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.01.002 · Cited by 106
Self-citationSteinparzer, I., Sedlyarov, V., Rubin, J. D., Eislmayr, K., Galbraith, M. D., Levandowski, C. B., Vcelkova, T., Sneezum, L., Wascher, F., Amman, F., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.034 · Cited by 105
Self-citationDissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors
Parua, P. K., & Fisher, R. P. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0563-4 · Cited by 105
Clarke, P. A., Ortiz-Ruiz, M.-J., Poele, R. T., Adeniji-Popoola, O., Box, G., Court, W., Czasch, S., Bawab, S. E., Esdar, C., Ewan, K., et al. (2016) · eLife · doi:10.7554/elife.20722 · Cited by 99
CDK8 Kinase Activity Promotes Glycolysis
Galbraith, M. D., Andrysík, Z., Pandey, A., Hoh, M., Bonner, E. A., Hill, A. A., Sullivan, K. D., & Espinosa, J. M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.058 · Cited by 103
Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8
Hatcher, J. M., Wang, E. S., Johannessen, L. H., Kwiatkowski, N. P., Sim, T., & Gray, N. S. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00011 · Cited by 94
Liang, J., Chen, M., Hughes, D. T., Chumanevich, A. A., Altilia, S., Kaza, V., Lim, C., Kiaris, H., Mythreye, K., Peña, M. M. O., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1583 · Cited by 91
Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
Dannappel, M., Sooraj, D., Loh, J. J., & Firestein, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00171 · Cited by 90
Fish, E. N., & Platanias, L. C. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0450 · Cited by 92
Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells
Koehler, M. F. T., Bergeron, P., Blackwood, E. M., Bowman, K. K., Clark, K., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00278 · Cited by 85
Tymoszuk, P., Charoentong, P., Hackl, H., Seeboeck, R., Müller‐Holzner, E., Trajanoski, Z., Obrist, P., Révillion-Carette, F., Peyrat, J., Fiegl, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-257 · Cited by 80
A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response
Audetat, K. A., Galbraith, M. D., Odell, A. T., Lee, T., Pandey, A., Espinosa, J. M., Dowell, R. D., & Taatjes, D. J. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00626-16 · Cited by 75
Self-citationCDK8 kinase—An emerging target in targeted cancer therapy
Rzymski, T., Mikuła, M., Wiklik, K., & Brzózka, K. D. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.05.011 · Cited by 77
STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia
Maurer, B., Kollmann, S., Pickem, J., Hoelbl‐Kovacic, A., & Sexl, V. (2019) · Cancers · doi:10.3390/cancers11111726 · Cited by 79
New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation
Wells, A. D., & Morawski, P. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3625 · Cited by 78
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance
Hofmann, M. H., Mani, R., Engelhardt, H., Impagnatiello, M. A., Carotta, S., Kerenyi, M. A., Lorenzo‐Herrero, S., Böttcher, J., Scharn, D., Arnhof, H., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0789 · Cited by 76
A precisely positioned MED12 activation helix stimulates CDK8 kinase activity
Klatt, F., Leitner, A., Kim, I. V., Ho-Xuan, H., Schneider, E. V., Langhammer, F., Weinmann, R., Müller, M., Huber, R., Meister, G., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917635117 · Cited by 78
Self-citationNuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA
Liu, S., Jiang, M., Wang, W., Liu, W., Song, X., Ma, Z., Zhang, S., Liu, L., Liu, Y., & Cao, X. (2017) · Nature Immunology · doi:10.1038/s41590-017-0003-0 · Cited by 76
Saleiro, D., & Platanias, L. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101299 · Cited by 76
Chen, M., Li, J., Zhang, L., Wang, L., Cheng, C., Ji, H., Altilia, S., Ding, X., Cai, G., Altomare, D., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad538 · Cited by 71
Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells
Johannessen, L. H., Sundberg, T. B., O'Connell, D. J., Kolde, R., Berstler, J., Billings, K., Khor, B., Seashore-Ludlow, B. A., Fassl, A., Russell, C. N., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2458 · Cited by 73
Cyclin-dependent kinase activity is required for type I interferon production
Cingöz, O., & Goff, S. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720431115 · Cited by 68
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
Menzl, I., Zhang, T., Berger‐Becvar, A., Grausenburger, R., Heller, G., Prchal‐Murphy, M., Edlinger, L., Knab, V. M., Uras, I. Z., Grundschober, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12656-x · Cited by 69
CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway
Fukasawa, K., Kadota, T., Horie, T., Tokumura, K., Terada, R., Kitaguchi, Y., Park, G., Ochiai, S., Iwahashi, S., Okayama, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01745-1 · Cited by 65
Calpena, E., Hervieu, A., Kaserer, T., Swagemakers, S. M. A., Goos, J. A. C., Adeniji-Popoola, O., Ortiz-Ruiz, M. J., Barbaro‐Dieber, T., Bownass, L., Brilstra, E. H., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.006 · Cited by 64
Wienerroither, S., Shukla, P., Farlik, M., Majoros, A., Stych, B., Vogl, C., Cheon, H., Stark, G. R., Strobl, B., Müller, M. M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.021 · Cited by 63
Self-citationLynch, C. J., Bernad, R., Martínez‐Val, A., Shahbazi, M. N., Pereira, S. N., Calvo, I., Blanco‐Aparicio, C., Tarantino, C., Garreta, E., Richart, L., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0573-1 · Cited by 65
Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8
Bergeron, P., Koehler, M. F. T., Blackwood, E. M., Bowman, K. K., Clark, K., Firestein, R., Kiefer, J. R., Maskos, K., McCleland, M. L., Orren, L., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00044 · Cited by 63
Tian, B., Zhao, Y., Kalita, M. K., Edeh, C. B., Paessler, S., Casola, A., Teng, M. N., Garofalo, R. P., & Brasier, A. R. (2013) · Journal of Virology · doi:10.1128/jvi.03399-12 · Cited by 61
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis
Berger, A., Hoelbl‐Kovacic, A., Bourgeais, J., Hoefling, L., Warsch, W., Grundschober, E., Uras, I. Z., Menzl, I., Putz, E. M., Hoermann, G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.351 · Cited by 62
Chen, M., Li, J., Liang, J., Thompson, Z. S., Kathrein, K., Broude, E. V., & Roninson, I. B. (2019) · Cells · doi:10.3390/cells8111413 · Cited by 57
Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders
Margolskee, E. M., Jobanputra, V., Jain, P., Chen, J., Ganapathi, K. A., Nahum, O., Levy, B., Morscio, J., Murty, V., Tousseyn, T., et al. (2016) · OncoTarget · doi:10.18632/oncotarget.9400 · Cited by 55
Walker, E. C., Johnson, R. W., Hu, Y., Brennan, H. J., Poulton, I. J., Zhang, J., Jenkins, B. J., Smyth, G. K., Nicola, N. A., & Sims, N. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.748483 · Cited by 57
Majoros, A., Platanitis, E., Szappanos, D., Cheon, H., Vogl, C., Shukla, P., Stark, G. R., Sexl, V., Schreiber, R. D., Schindler, C., et al. (2016) · EMBO Reports · doi:10.15252/embr.201540726 · Cited by 55
Self-citationLloyd, R. L., Urban, V., Muñoz‐Martínez, F., Ayestaran, I., Thomas, J. C., de Renty, C., O’Connor, M. J., Forment, J. V., Galanty, Y., & Jackson, S. P. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab628 · Cited by 56
Guo, Z., Wang, G., Lv, Y., Wan, Y. Y., & Zheng, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01988 · Cited by 54
Angel or Devil ? - CDK8 as the new drug target
Wu, D., Zhang, Z., Chen, X., Yan, Y., & Liu, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113043 · Cited by 54
Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation
Niţulescu, I., Meyer, S. C., Wen, Q. J., Crispino, J. D., Lemieux, M. E., Levine, R. L., Pelish, H. E., & Shair, M. D. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.013 · Cited by 55
CDK8-Novel Therapeutic Opportunities
Menzl, I., Witalisz‐Siepracka, A., & Sexl, V. (2019) · Pharmaceuticals · doi:10.3390/ph12020092 · Cited by 52
IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling
Padmanabhan, S., Gaire, B., Zou, Y., Uddin, M. M., & Vancurova, I. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110400 · Cited by 52
Ding, X., Sharko, A. C., McDermott, M. S. J., Schools, G. P., Chumanevich, A. A., Ji, H., Li, J., Zhang, L., Mack, Z. T., Sikirzhytski, V., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2201073119 · Cited by 49
Nakamura, A., Nakata, D., Kakoi, Y., Kunitomo, M., Murai, S., Ebara, S., Hata, A., & Hara, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24414 · Cited by 50
STAT1 is required to establish but not maintain interferon‐γ‐induced transcriptional memory
Tehrani, S., Mikulski, P., Abdul‐Zani, I., Mata, J. F., Siwek, W., & Jansen, L. E. T. (2023) · The EMBO Journal · doi:10.15252/embj.2022112259 · Cited by 47
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia
Berger, A., Sexl, V., Valent, P., & Moriggl, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2465 · Cited by 51
NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
Witalisz-Siepracka, A., Gotthardt, D., Prchal-Murphy, M., Didara, Z., Menzl, I., Prinz, D., Edlinger, L., Putz, E. M., & Sexl, V. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0183 · Cited by 47
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer
Becker, F., Joerg, V., Hupe, M. C., Roth, D., Krupar, R., Lubczyk, V., Kuefer, R., Sailer, V. W., Duensing, S. M., Kirfel, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32551 · Cited by 47
CDK8 Fine-Tunes IL-6 Transcriptional Activities by Limiting STAT3 Resident Time at the Gene Loci
Martínez‐Fábregas, J., Wang, L., Pöhler, E., Cozzani, A., Wilmes, S., Kazemian, M., Mitra, S., & Moraga, I. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108545 · Cited by 49
Nuclear ADP-ribosylation drives IFNγ-dependent STAT1α enhancer formation in macrophages
Gupte, R., Nandu, T. S., & Kraus, W. L. (2021) · Nature Communications · doi:10.1038/s41467-021-24225-2 · Cited by 48
Li, X., Wang, F., Xu, X., Zhang, J., & Xu, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636595 · Cited by 49
MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase
Sooraj, D., Sun, C. X., Doan, A., Garama, D. J., Dannappel, M., Zhu, D., Chua, H. K., Mahara, S., Hassan, W. A. W., Tay, Y. K., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.015 · Cited by 46
Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes
He, L., Zhu, Y., Fan, Q.-Z., Miao, D., Zhang, S., Liu, X., & Zhang, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.065 · Cited by 45
Greber, B. J., & Nogales, E. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-28151-9_5 · Cited by 43
Wang, M., Lin, R., Li, J., Suo, Y., Gao, J., Liu, L., Zhou, L., Ni, Y., Yang, Z., Zheng, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02045 · Cited by 45
Wu, L., Qin, Y., Xia, S., Dai, M., Han, X., Wu, Y., Zhang, X., Ma, J., Wang, Y., Tang, Y., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39543 · Cited by 40
Semper, C., Leitner, N. R., Lassnig, C., Parrini, M., Mahlakõiv, T., Rammerstorfer, M., Lorenz, K., Rigler, D., Müller, S., Kolbe, T., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00295-14 · Cited by 42
Self-citationMED 12 mutations and NOTCH signalling in chronic lymphocytic leukaemia
Wu, B., Slabicki, M. M., Sellner, L., Dietrich, S., Liu, X., Jethwa, A., Hüllein, J., Walther, T., Wagner, L., Huang, Z., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14869 · Cited by 41
Zhang, L., Cheng, C., Li, J., Wang, L., Chumanevich, A. A., Porter, D. C., Mindich, A., Gorbunova, S., Roninson, I. B., Chen, M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01951 · Cited by 40
Kiritsy, M. C., Ankley, L. M., Trombley, J. D., Huizinga, G. P., Lord, A. E., Orning, P., Elling, R., Fitzgerald, K. A., & Olive, A. J. (2021) · eLife · doi:10.7554/elife.65110 · Cited by 34
Kościuczuk, E. M., Mehrotra, S., Saleiro, D., Kroczyńska, B., Majchrzak-Kita, B., Lisowski, P., Driehaus, C., Rogalska, A., Turner, A. E., Lienhoop, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005956 · Cited by 39
Yamamoto, S., Hagihara, T., Horiuchi, Y., Okui, A., Wani, S., Yoshida, T., Inoué, T., Tanaka, A., Ito, T., Hirose, Y., et al. (2017) · Genes to Cells · doi:10.1111/gtc.12475 · Cited by 38
Miao, Y., Gambini, A., Zhang, Y., Padilla‐Banks, E., Jefferson, W. N., Bernhardt, M. L., Huang, W., Li, L., & Williams, C. J. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy004 · Cited by 37
Sharko, A. C., Lim, C., McDermott, M. S. J., Hennes, C., Philavong, K. P., Aiken, T., Tatarskiy, V. V., Roninson, I. B., & Broude, E. V. (2021) · Cells · doi:10.3390/cells10010144 · Cited by 36
Chen, T., Tsai, M.-H., Kung, J. T., Lin, K., Decker, T., & Lee, C. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151620 · Cited by 37
Ono, K., Banno, H., Okaniwa, M., Hirayama, T., Iwamura, N., Hikichi, Y., Murai, S., Hasegawa, M., Hasegawa, Y., Yonemori, K., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.038 · Cited by 36
Competitive binding of STATs to receptor phospho-Tyr motifs accounts for altered cytokine responses
Wilmes, S., Jeffrey, P.-A., Martínez‐Fábregas, J., Hafer, M., Fyfe, P. K., Pöhler, E., Gaggero, S., López‐García, M., Lythe, G., Taylor, C., et al. (2021) · eLife · doi:10.7554/elife.66014 · Cited by 35
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 38
Xiao, J., Liang, J., Fan, J., Hou, P., Li, X., Zhang, H., Li, K., Bu, L., Li, P., He, M., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3656 · Cited by 35
Hermand, P., Azouzi, S., Gautier, E., Guillonneau, F., Bondet, V., Duffy, D., Dechavanne, S., Tharaux, P., Mayeux, P., Kim, C. L. V., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.238295 · Cited by 34
Metadata
- Authors
- Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., & Kovarik, P.
- Affiliations
- University of Vienna (AT)
- University of Colorado Boulder (US)
- University of Cambridge (GB)
- University of Veterinary Medicine Vienna (AT)
- Corresponding author
- Kovarik, Pavel
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 38
- Issue
- 2
- Pages
- 250-262
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC3580287
- OpenAlex
- W2059553622
- Cited by
- 297
- References
- 53
- Citations by year
- 2026: 32 · 2025: 28 · 2024: 29 · 2023: 21 · 2022: 23 · 2021: 20 · 2020: 24 · 2019: 27 · 2018: 19 · 2017: 24 · 2016: 15 · 2015: 13 · 2014: 13 · 2013: 9
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Immunity (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund
- Universität Wien
- National Institutes of Health
- National Cancer Institute (R01CA127364, P30CA046934)
- National Institute of General Medical Sciences (T32-GM08759, T32GM008759, T32GM142607)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- CDK8, STAT1, STAT3, STAT5, serine phosphorylation, transactivation domain, Mediator complex, interferon signaling, interferon-gamma, antiviral response, RNA polymerase II occupancy, gene expression regulation
- MeSH terms
- Animals, Fibroblasts, Gene Expression Regulation, Humans, Interferon-gamma, Phosphorylation, Promoter Regions, Genetic, RNA Polymerase II, Transcription, Genetic, Signal Transduction, Interleukin-6, Vesiculovirus, Oligonucleotide Array Sequence Analysis, STAT1 Transcription Factor, STAT3 Transcription Factor, STAT5 Transcription Factor, Mice, Cyclin-Dependent Kinase 8, Hep G2 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
